Amir Faridmoayer

As Chief Scientific Officer of GlycoEra, Amir is an expert in glycobiology and glycoengineering and responsible for defining the scientific research strategy of the company. He leads the identification of new products, technologies and scientific opportunities for the growth of the company and drives the scientific exchange with key opinion leaders and the Scientific Advisory Board.

Prior to GlycoEra Amir was a co-founder and CSO of LimmaTech Biologics, responsible for defining scientific strategy for development of vaccines and biotherapeutics. Prior to LimmaTech, he was Head of Discovery and a member of the management team at GlycoVaxyn AG at the time of its acquisition by GlaxoSmithKline plc in February 2015. He established the Discovery department of GlycoVaxyn in 2013 where he was responsible for the development of proprietary research projects and platforms. He has 20 years’ experience in glycobiology and glycoengineering, and pioneered several glycoengineering platforms, including vaccine bioconjugation and therapeutic CustomGlycan platforms. Amir obtained his PhD in 2005 from the University of British Columbia, Canada, followed by Post-Doctoral Fellowships at the Alberta Glycomic Center, University of Alberta and Institute of Microbiology at ETH. He is the author of several peer-reviewed articles and an inventor of several granted patents.